dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Bacoyiannis, Charalambos | en |
dc.contributor.author | Karvounis, N. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Fountzilas, George | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Bacoyiannis, Charalambos | en |
dc.creator | Karvounis, N. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.date.accessioned | 2018-06-22T09:52:30Z | |
dc.date.available | 2018-06-22T09:52:30Z | |
dc.date.issued | 1998 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41384 | |
dc.description.abstract | Twenty-three patients with advanced melanoma were treated with a combination of subcutaneous recombinant human interleukin-2 (IL-2), and recombinant interferon alpha-2a (IFN-alpha) with chemotherapy consisting of four cycles of carboplatin (300 mg/m2, day 1) and vinblastine (6 mg/m2, day 1), every 28 days (CV-IL-IF). IL-2 was given at a dose of 4.5 x 10(6) U twice daily on days 3-6 and days 21-24 of each cycle; IFN-alpha dose was 4.5 x 10(6) U, starting on day 2, thrice weekly. Immunotherapy was intended to continue for 6 months. Of the 23 analyzed patients, 4 (17%) achieved an objective response, including 1 complete and 3 partial responses, in nonvisceral metastatic disease. The median time to progression was 5 months and the median survival from onset of the treatment 6 months (range 1-14 months). Four patients discontinued the treatment, due to nonhaematologic toxicity; 3 for severe weakness and the 4th patient for long-lasting CNS side-effects. Other grade 3-4 toxicities included weight loss (22%), nausea and vomiting (17%) and alopecia (13%). The haematologic toxicity was acceptable. No toxic death was noted. It is concluded that the CV-IL-IF regimen has limited activity and moderate toxicity. | en |
dc.language.iso | eng | en |
dc.source | Oncology | en |
dc.subject | Adult | en |
dc.subject | Female | en |
dc.subject | Male | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Aged | en |
dc.subject | Humans | en |
dc.subject | Middle aged | en |
dc.subject | Chemotherapy | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Phytogenic | en |
dc.subject | Prospective studies | en |
dc.subject | Treatment outcome | en |
dc.subject | Vinblastine | en |
dc.subject | Survival analysis | en |
dc.subject | Adjuvant | en |
dc.subject | Carboplatin | en |
dc.subject | Injections | en |
dc.subject | Interferon-alpha | en |
dc.subject | Interleukin-2 | en |
dc.subject | Melanoma | en |
dc.subject | Skin neoplasms | en |
dc.subject | Subcutaneous | en |
dc.title | Subcutaneous low doses of interleukin-2 and recombinant interferon alpha with carboplatin and vinblastine in patients with advanced melanoma | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 55 | |
dc.description.issue | 1 | |
dc.description.startingpage | 48 | |
dc.description.endingpage | 52 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |